Project Information

• Status: 27 molecules were patented. Funded by "Milgrom Family Support Program of the Hebrew University of Jerusalem"

Peroxisome Proliferator-Activated Receptors (PPARs) are a subgroup of the nuclear hormone receptor family. Its members, PPAR-α, PPAR-γ and PPAR-δ (also called PPAR-β) are ligand-activated transcription factors. PPAR agonists can be beneficial under different scenarios. PPAR-δ agonist (GW501516) has beneficial effects on obesity, insulin resistance and reduces plasma glucose in rodent models of type 2 diabetes. Studies on obese primates suggest this agonist decreases low-density lipoprotein (LDL), TG and insulin, and increases HDL. Our discovery and patenting of a large set of 27 PPAR-δ leads (13 low nm) and hits (low µm) agonists, most of which are selective to other PPARs, needs to be elucidated as potential agents to increase physical endurance in the field under several weather conditions, besides the effect of such agonists on wound healing of several types. Proof of such beneficial effects by any of these candidate agents in small animals may be extended after that to human clinical studies with the hope to retain similar characteristics.